| Name | Oxford Biomedica |
|---|---|
| Epic | OXB |
| Isin | GB00BDFBVT43 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 412.50p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £436.93 | Debt ratio | n/a |
| Shares in issue | 100.01 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -11.69 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -41.29 | 52-week high / low | 166.80p / 445.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Oxford Biomedica |
|---|---|
| Address | Windrush Court, Transport Way, Oxford, United Kingdom, OX4 6LT |
| Telephone | +44 (0) 1865 783 000 |
| Website | http://www.oxb.com/ |
| Director | Position |
|---|---|
| Dr Frank Mathias | CEO |
| Mr Stuart Paynter | CFO |
| Mr Peter Soelkner | Non-Executive Director |
| Dr Michael Hayden | Non-Executive Director |
| Mr Robert Ghenchev | Non-Executive Director |
| Mr Dame Kay Davies | Senior Independent Director |
| Mr Stuart Henderson | Vice Chairman |
| Dr Roch Doliveux | Chairman and CEO |
| Ms Namrata P Patel | Independent Non-Executive Director |
| Ms Catherine Moukheibir | Independent Non-Executive Director |
| Dr Heather Preston | Independent Non-Executive Director |
| Ms Leone Patterson | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 105.89 | 0.05 | 0.07 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 244.68 | 73.39 | 75.98 |
| Inventory / work in progress | 12.62 | 9.52 | 6.91 |
| Trade and other receivables | 61.57 | 44.75 | 53.93 |
| Cash and equivalents | 141.28 | 108.94 | 46.74 |
| Other current assets and asset held for resale | 0.02 | 0.63 | 0.37 |
| Total of all assets | 460.18 | 237.23 | 183.93 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 59.66 | 33.31 | 52.45 |
| Long term liabilities | 164.32 | 16.58 | 18.73 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 223.99 | 49.89 | 71.18 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 236.19 | 187.34 | 112.75 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 48.13 | 43.09 | 41.16 |
| Minority interests | 31.54 | n/a | n/a |
| Retained earnings | -198.54 | -165.81 | -188.72 |
| Share premium account | 379.95 | 307.77 | 258.02 |
| Total equity | 236.19 | 187.34 | 112.75 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -30.22 | 20.77 | -5.69 |
| Pre-tax profit | -45.98 | 19.88 | -6.57 |